Advertisement

Topics

Samsung Bioepis Co., Ltd. Company Profile

06:25 EST 20th February 2017 | BioPortfolio

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to increasing patient access to affordable, high-quality biologic medicines. Through innovations in product development and quality assurance, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com.


News Articles [217 Associated News Articles listed on BioPortfolio]

EMA reviewing Samsung Bioepis biosimilar of Herceptin

Samsung Bioepis said EMA accepted for review an MAA for SB3, a biosimilar of Herceptin trastuzumab from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY).Herceptin is approved to treat early and...

Catalent to work with Samsung Bioepis on biosim production

Global CMO Catalent will help Samsung Bioepis supply its Enbrel biosimilar in Europe, where it is marketed by Biogen. 

EMA accepts Samsung Bioepis’ Herceptin biosimilar application for review

South Korean drug developer Samsung Bioepis is closer to bring another biosimilar to the European market…

UPDATE 1-Samsung Bioepis seeks Europe approval for copy of Herceptin breast cancer drug

* Top shareholder Samsung BioLogics planning S.Korea IPO (Updates with comments from Bioepis, BioLogics IPO details)

Samsung Bioepis seeks Europe approval for its Herceptin copy

SEOUL, Oct 4 (Reuters) - Biosimilars maker Samsung Bioepis, part of South Korea's top conglomerate Samsung Group, said on Tuesday it is seeking regulatory approval in Europe to sell its copy of Roche'...

Samsung Bioepis contracts Catalent to help commercialize Benepali

Samsung Bioepis has contracted Catalent to provide fill finish services for its Enbrel (etanercept) biosimilar, Benepali.

La Agencia Europea de Medicamentos (EMA) Aceptó Evaluar la Solicitud de Autorización para la Comercialización del Candidato a Biosimilar SB3 Trastuzumab de Samsung Bioepis

Tuesday, October 4th 2016 at 10:34am UTC SB3, un candidato a biosimilar referido a Herceptin® (trastuzumab), es el primer candidato a biosimilar oncológico de Samsung Bioepis presentado para su eval...

Samsung Bioepis Herceptin biosimilar accepted for review in EU

The EMA will assess a version of Roche’s breast cancer drug Herceptin (trastuzumab), the fifth biosimilar candidate submitted for review by Samsung Bioepis.

Drugs and Medications [0 Results]

None

PubMed Articles [6 Associated PubMed Articles listed on BioPortfolio]

Clinical outcomes of tissue expanders on adjuvant radiotherapy of resected retroperitoneal sarcoma.

We investigated the efficacy and safety of a tissue expander (TE) for adjuvant radiotherapy (RT) of resected retroperitoneal sarcoma (RPS).This study was conducted with 37 patients with RPS who receiv...

Measuring the operational efficiency of individual theme park attractions.

This study assesses the operation efficiency of theme park attractions using the data envelopment analysis, utilizing actual data on 15 attractions at Samsung Everland located in Yongin-si, Republic o...

Tissue expander placement and adjuvant radiotherapy after surgical resection of retroperitoneal liposarcoma offers improved local control.

Given that retroperitoneal liposarcoma (LPS) is extremely difficult to completely resect, and has a relatively high rate of recurrence, radiotherapy (RT) is the treatment of choice after surgical rese...

Tissue expander placement and adjuvant radiotherapy after surgical resection of retroperitoneal liposarcoma offers improved local control.

Given that retroperitoneal liposarcoma (LPS) is extremely difficult to completely resect, and has a relatively high rate of recurrence, radiotherapy (RT) is the treatment of choice after surgical rese...

Conditional disease-free survival among patients with breast cancer.

Conditional disease-free survival (CDFS) reflects changes over time. Because traditional disease-free survival (DFS) is estimated from the date of diagnosis, it is limited in the ability to predict ri...

Clinical Trials [13 Associated Clinical Trials listed on BioPortfolio]

Evaluation of the Samsung LABGEO IVD-A20 CHF Test in a Point-of-Care Setting

To establish the performance characteristics of the Samsung LABGEO IVD-A20 CHF Test in intended use settings, by comparing test results of the A20 CHF Test with results obtained from an FD...

Gait Pattern Analysis and Feasibility of Gait Training With a Walking Assist Robot in Stroke Patients and Elderly Adults

The purpose of this study was to investigate the effects of the new wearable hip assist robot developed by Samsung Advanced Institute of Technology (Samsung Electronics Co, Ltd., Korea) to...

The Effect of a Walking Assist Robot on Gait Function and Brain Activity in Stroke Patients and Elderly Adults

The purpose of this study was to investigate the effects of the new wearable hip assist robot, gait enhancing mechatronic system (GEMS) developed by Samsung Advanced Institute of Technolog...

Samsung Medical Center-Lymphoma Cohort Study

The purpose of this study is to establish a model which can predict the treatment outcome and the risk of treatment-related morbidity in patients with lymphoma.

Database of Pelvic Inflammatory Disease

The aim of this prospective study is to collect data on in-patients with pelvic inflammatory disease(PID) at Kangbuk Samsung Hospital.

Companies [21 Associated Companies listed on BioPortfolio]

Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to increasing patient access to affordable, high-quality biologic medicines. Through innovations in p...

Samsung Electronics America

Samsung Electronics America, Inc. (SEA), based in Ridgefield Park, NJ, is a subsidiary of Samsung Electronics Co., Ltd. The company markets a broad range of award-winning consumer...

Samsung Electronics North America

Samsung Electronics North America (NAHQ), based in Ridgefield Park, NJ, is an arm of Samsung Electronics Co., Ltd. The company markets a broad range of award-winning consumer elec...

Samsung Electronics America, Inc.

Samsung Electronics America, Inc. (SEA), based in Ridgefield Park, NJ, is a subsidiary of Samsung Electronics Co., Ltd. The company markets a broad range of award-winning consumer...

Samsung Electronics America Inc.

As a global leader in Information Technology, Samsung’s Enterprise Business Division (EBD) is committed to introducing new business experiences across a diverse spectrum of i...

More Information about "Samsung Bioepis Co., Ltd." on BioPortfolio

We have published hundreds of Samsung Bioepis Co., Ltd. news stories on BioPortfolio along with dozens of Samsung Bioepis Co., Ltd. Clinical Trials and PubMed Articles about Samsung Bioepis Co., Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Samsung Bioepis Co., Ltd. Companies in our database. You can also find out about relevant Samsung Bioepis Co., Ltd. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record